CYP2C19基因检测指导ACS患者抗血小板药物应用的安全性和疗效观察被引量：1

下载PDF

导出

摘要目的:对经皮冠状动脉介入术(PCI)的急性冠脉综合征(ACS)患者进行CYP2C19基因多态性检测,指导PCI术后选择应用抗血小板药物并观察用药的安全性及疗效。方法:将接受PCI治疗的ACS患者652例分为替格瑞洛组256例,为氯吡格雷低代谢,用替格瑞洛替换治疗,常规治疗组396例,无氯吡格雷抵抗,应用氯吡格雷治疗,观察术后1个月及6个月的主要不良心血管事件(MACE)。结果:替格瑞洛组术后1个月时总MACE发生率与常规治疗组比较无显著差异(4.04%比3.91%,P=0.173),两组总体MACE发生率术后6个月比较时差异无统计学意义(6.57%比5.86%,P=0.210),但替格瑞洛组仍保持较低趋势。结论:ACS患者PCI术后进行CYP2C19基因多态性检测,对氯吡格雷用替格瑞洛替换治疗,可有效降低MACE发生率。

作者耿守孟贺东勇尹磊宫兴基李辉

机构地区青岛大学附属医院急诊科

出处《交通医学》 2017年第2期157-160,共4页 Medical Journal of Communications

基金青岛市黄岛区科技局资助项目(2014-1-82)

关键词急性冠脉综合征经皮冠状动脉介入术 CYP2C19基因替格瑞洛氯吡格雷

分类号 R540.46 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献5

1严晓伟.抗血小板药物的研发进展[J].中国循环杂志,2011,26(1):4-5. 被引量：31
2李国标,苏启表,古宏标,朱桂平,张卫,陈燕,刘思敏,张伯彬.ABCB1基因位点G2677T/A单核苷酸多态性与氯吡格雷抵抗的相关性研究[J].广东药学院学报,2013,29(5):552-556. 被引量：4
3Xie, Hong-Guang Zou, Jian-Jun Hu, Zuo-Ying Zhang, Jun-Jie Ye, Fei Chen, Shao-Liang.Individual variability in the disposition of and response to clopidogrel. Pharmacogenomics and beyond[J].南京医科大学学报（自然科学版）,2011,31(6):922-922. 被引量：20
4吴丹,杨胜利,路靖,黄洁,孙亚勤.冠心病患者支架术后根据检测药物代谢酶CYP2C19基因调整抗血小板治疗的价值[J].中国循环杂志,2015,30(3):216-219. 被引量：46
5成万钧,周玉杰,赵迎新,郭永和,王志坚,聂斌,王建龙.体重对冠状动脉介入术患者氯吡格雷负荷剂量后血小板聚集率的影响[J].中国循环杂志,2010,25(1):18-21. 被引量：11

二级参考文献25

1周健,吕虹,康熙雄.中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测[J].中国临床药理学与治疗学,2007,12(2):208-213. 被引量：84
2Wivioa SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement ifl Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON -- 11MI 38 ). Am Heart J,2006,152(4) :627-635.
3Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med,2009,361 : 1045-1057.
4Desai NR, Bhatt DL. The State of Periprocedural Antiplatelet Therapy After Recent Trials. JACC,2010,3(6) : 571-583.
5HOLMES D R,DEHMER G J,KAUL S,et al.ACCF/AHA clopidogrel clinical alert:approaches to the FDA "boxed warning":a report of the American college of cardiology foundation task force on clinical expert consensus documents and the American Heart Association endorsed by the society for cardiovascular angiography and interventions and the society of thoracic surgeons[J].J Am Coll Cardiol,2010,56(4):321-341.
6MIJAJLOVIC M D,SHULGA O,BLOCH S,et al.Clinical consequences of aspirin and clopidogrel resistance:an overview[J].Acta Neurol Scand,2013,128 (4):213-219.
7BANSILAL S,BHATT D L.Clopidogrel resistance-a clear problem with an unclear solution[J].Indian Heart J,2012,64(4):353-355.
8HASAN M S,BASRI H B,HIN L P,et al.Genetic polymorphisms and drug interactions leading to clopidogrel resistance:why the Asian population requires special attention[J].Int J Neurosci,2013,123 (3):143-154.
9BREIER A,GIBALOVA L,SERES M,et al.New insight into p-glycoprotein as a drug target[J].Anticancer Agents Med Chem,2013,13(1):159-170.
10MEGA J L,CLOSE S L,WIVIOTT S D,et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial:a pharmacogenetic analysis[J].Lancet,2010,376(9749):1312-1319.